A number of research firms have changed their ratings and price targets for Abbott Laboratories (NYSE: ABT):

  • 7/14/2017 – Abbott Laboratories had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $55.00 price target on the stock, up previously from $48.00.
  • 7/11/2017 – Abbott Laboratories had its “hold” rating reaffirmed by analysts at BMO Capital Markets. They now have a $48.00 price target on the stock.
  • 7/10/2017 – Abbott Laboratories had its “equal weight” rating reaffirmed by analysts at Morgan Stanley.
  • 7/3/2017 – Abbott Laboratories was upgraded by analysts at TheStreet from a “c+” rating to a “b” rating.
  • 6/30/2017 – Abbott Laboratories had its “outperform” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $54.00 price target on the stock, up previously from $47.50.
  • 6/29/2017 – Abbott Laboratories is now covered by analysts at Guggenheim. They set a “buy” rating and a $58.00 price target on the stock.
  • 6/29/2017 – Abbott Laboratories had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $58.00 price target on the stock.
  • 6/21/2017 – Abbott Laboratories is now covered by analysts at BTIG Research. They set a “buy” rating and a $56.00 price target on the stock.
  • 6/21/2017 – Abbott Laboratories was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $55.00 price target on the stock. According to Zacks, “For the majority of last one month, Abbott is trading above the broader Medical Products industry. We are optimistic about the company’s strong and consistent EPD and Medical Devices performance in the last reported first quarter. Overall, the company stands to benefit from the ongoing integration and synergy achievement of St. Jude. We are also looking forward to the company’s plans to focus on selling portfolio in core therapeutic areas. Recently, Abbott received CE mark for its TactiCath Sensor and Confirm Rx ICM products which is quite encouraging. The company also launched science-based nutrition drinks for better recovery from surgeries. On the flip side, Abbott’s sluggish pediatric business in China continues to hamper growth. Management is also concerned about the on-going economic problem in Venezuela that is expected to remain unresolved in the coming quarters.”
  • 6/20/2017 – Abbott Laboratories was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “For the majority of last one month, Abbott is trading above the broader Medical Products industry. We are optimistic about the company’s strong and consistent EPD and Medical Devices performance in the last reported first quarter. Overall, the company stands to benefit from the ongoing integration and synergy achievement of St. Jude. We are also looking forward to the company’s plans to focus on selling portfolio in core therapeutic areas. Recently, Abbott received CE mark for its TactiCath Sensor and Confirm Rx ICM products which is quite encouraging. The company also launched science-based nutrition drinks for better recovery from surgeries. On the flip side, Abbott’s sluggish pediatric business in China continues to hamper growth. Management is also concerned about the on-going economic problem in Venezuela that is expected to remain unresolved in the coming quarters.”
  • 6/17/2017 – Abbott Laboratories was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 6/16/2017 – Abbott Laboratories had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $55.00 price target on the stock.
  • 6/14/2017 – Abbott Laboratories was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $53.00 price target on the stock. According to Zacks, “For the majority of last one month, Abbott is trading above the broader Medical Products industry. We are optimistic about the company’s strong and consistent EPD and Medical Devices performance in the last reported first quarter. Overall, the company stands to benefit from the ongoing integration and synergy achievement of St. Jude. We are also looking forward to the company’s plans to focus on selling portfolio in core therapeutic areas. Very recently, Abbott also received CE mark for its TactiCath Sensor and Confirm Rx ICM products which is quite encouraging. The company also launched science-based nutrition drinks for better recovery from surgeries. On the flip side, Abbott’s sluggish pediatric business in China continues to hamper growth. Management is also concerned about the on-going economic problem in Venezuela that is expected to remain unresolved in the coming quarters.”
  • 6/13/2017 – Abbott Laboratories was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “For the majority of last one month, Abbott is trading above the broader Medical Products industry. We are optimistic about the company’s strong and consistent EPD and Medical Devices performance in the last reported first quarter. Overall, the company stands to benefit from the ongoing integration and synergy achievement of St. Jude. We are also looking forward to the company’s plans to focus on selling portfolio in core therapeutic areas. Very recently, Abbott also received CE mark for its TactiCath Sensor and Confirm Rx ICM products which is quite encouraging. The company also launched science-based nutrition drinks for better recovery from surgeries. On the flip side, Abbott’s sluggish pediatric business in China continues to hamper growth. Management is also concerned about the on-going economic problem in Venezuela that is expected to remain unresolved in the coming quarters.”
  • 6/1/2017 – Abbott Laboratories was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $51.00 price target on the stock. According to Zacks, “For the majority of last one month, Abbott is trading above the broader Medical Products industry. We are optimistic about the company’s strong and consistent EPD and Medical Devices performance in the last reported first quarter. Overall, the company stands to benefit from the ongoing integration and synergy achievement of St. Jude. We are also looking forward to the company’s plans to focus on selling portfolio in core therapeutic areas. Very recently, Abbott also received CE mark for its TactiCath Sensor and Confirm Rx ICM products which is quite encouraging. The company also launched science-based nutrition drinks for better recovery from surgeries. On the flip side, Abbott’s sluggish pediatric business in China continues to hamper growth. Management is also concerned about the on-going economic problem in Venezuela that is expected to remain unresolved in the coming quarters.”
  • 5/31/2017 – Abbott Laboratories had its price target raised by analysts at Stifel Nicolaus from $49.00 to $51.00. They now have a “buy” rating on the stock.
  • 5/31/2017 – Abbott Laboratories was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “For the majority of last one month, Abbott is trading above the broader Medical Products industry. We are optimistic about the company’s strong and consistent EPD and Medical Devices performance in the last reported first quarter. Overall, the company stands to benefit from the ongoing integration and synergy achievement of St. Jude. We are also looking forward to the company’s plans to focus on selling portfolio in core therapeutic areas. Very recently, Abbott also received CE mark for its TactiCath Sensor and Confirm Rx ICM products which is quite encouraging. The company also launched science-based nutrition drinks for better recovery from surgeries. On the flip side, Abbott’s sluggish pediatric business in China continues to hamper growth. Management is also concerned about the on-going economic problem in Venezuela that is expected to remain unresolved in the coming quarters.”
  • 5/26/2017 – Abbott Laboratories was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $49.00 price target on the stock. According to Zacks, “For the majority of last one month, Abbott is trading above the broader Medical Products industry. We are optimistic about the company’s strong and consistent EPD and Medical Devices performance in the last reported first quarter. Overall, the company stands to benefit from the ongoing integration and synergy achievement of St. Jude. We are also looking forward to the company’s plans to focus on selling portfolio in core therapeutic areas. Very recently, Abbott also received CE mark for its TactiCath Sensor and Confirm Rx ICM products which is quite encouraging. The company also launched science-based nutrition drinks for better recovery from surgeries. On the flip side, Abbott’s sluggish pediatric business in China continues to hamper growth. Management is also concerned about the on-going economic problem in Venezuela that is expected to remain unresolved in the coming quarters.”
  • 5/24/2017 – Abbott Laboratories was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Over the last three months, Abbott is trading below the broader Medical Products industry. While, sluggish pediatric business in China continues to hamper growth, we are also worried about the on-going economic problem in Venezuela that is expected to remain unresolved in the coming quarters. On a positive note, we are optimistic about its strong and consistent EPD and Medical Devices performance in the last reported first quarter. Overall, the company stands to benefit from the ongoing integration and synergy achievement of St. Jude. We are also looking forward to the company’s plans to focus on selling portfolio in core therapeutic areas. Very recently, Abbott also received CE mark for its TactiCath Sensor and Confirm Rx ICM products which is quite encouraging.”

Shares of Abbott Laboratories (NYSE ABT) opened at 48.76 on Tuesday. Abbott Laboratories has a 1-year low of $37.38 and a 1-year high of $49.59. The stock has a market capitalization of $84.61 billion, a P/E ratio of 50.74 and a beta of 1.06. The stock has a 50 day moving average of $46.26 and a 200-day moving average of $43.65.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, April 19th. The healthcare product maker reported $0.48 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.43 by $0.05. Abbott Laboratories had a net margin of 6.74% and a return on equity of 14.91%. The business had revenue of $6.34 billion for the quarter, compared to analysts’ expectations of $6.16 billion. During the same period last year, the company earned $0.41 earnings per share. The company’s quarterly revenue was up 29.7% on a year-over-year basis. Equities research analysts predict that Abbott Laboratories will post $2.47 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, August 15th. Investors of record on Friday, July 14th will be given a $0.265 dividend. The ex-dividend date of this dividend is Wednesday, July 12th. This represents a $1.06 annualized dividend and a dividend yield of 2.17%. Abbott Laboratories’s dividend payout ratio is presently 110.42%.

In related news, insider Joseph J. Manning sold 4,200 shares of the firm’s stock in a transaction that occurred on Wednesday, April 26th. The shares were sold at an average price of $43.95, for a total value of $184,590.00. Following the sale, the insider now directly owns 26,224 shares of the company’s stock, valued at $1,152,544.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jared Watkin sold 552 shares of the firm’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $47.97, for a total transaction of $26,479.44. Following the completion of the sale, the insider now directly owns 47,090 shares in the company, valued at $2,258,907.30. The disclosure for this sale can be found here. Insiders sold 206,902 shares of company stock worth $9,497,761 over the last three months. Corporate insiders own 0.76% of the company’s stock.

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.